SAPHNA Professional Officer Sharon White said: "We have spoken directly with the supplier who advised that there are no stocks available due to minimal quality issues. They added that the MHRA advice is that children and young people should continue to use any in date Jext pens that they currently have provided."
Many people diagnosed with anaphylaxis carry a Jext adrenaline auto-injector at all times in case they experience a reaction. However, concerns have been raised over stock shortages.
This has been confirmed by the product distributor, ALK-Abello, who has apologised about the temporary delay of the 300mcg pen and says it is working to resolve the situation as soon as possible – further supplies will be available mid-December.
It adds that advice issued by the Medicines and Healthcare products Regulatory Agency (MHRA) is for people to continue using any in-date Jext pens. The Anaphylaxis Campaign, which is awaiting updates of supplies of the 150mg Jext, issues this advice to those who do not have any spare ones:
"If allergic patients are having problems getting a Jext 300mcg, their pharmacist should be able to dispense an alternative injector (they may have to discuss/check first with the person who prescribed the injector). If this happens, they should make absolutely sure that they are shown how to use the alternative device as it is likely to be administered in a slightly different way to Jext.
"In the unlikely event that an alternative device is not available and they have an adrenaline injector that has recently passed its expiry date, it is better to use this device than not use it at all. After using your injector, dial 999 or get someone else to do it. Immediately after your adrenaline has been administered you will need to get to hospital because the symptoms can return and you may need further treatment."
For further advice and any concerns, call the Anaphylaxis Campaign helpline on 01252 542029.